{"url":"https://lda.senate.gov/api/v1/filings/4884a188-fac3-418a-9df9-e22a780f23bb/","filing_uuid":"4884a188-fac3-418a-9df9-e22a780f23bb","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2023,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/4884a188-fac3-418a-9df9-e22a780f23bb/print/","filing_document_content_type":"text/html","income":null,"expenses":"1500000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Daniel Bachner","dt_posted":"2023-04-20T16:09:33-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1399 New York Avenue NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401049961,"url":"https://lda.senate.gov/api/v1/registrants/401049961/","house_registrant_id":null,"name":"ABBVIE, INC.","description":"Biopharmaceutical company","address_1":"1399 New York Avenue NW","address_2":"Suite 600","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DANIEL BACHNER","contact_telephone":"+1 202-383-9616","dt_updated":"2026-01-08T13:23:19.652687-05:00"},"client":{"id":197319,"url":"https://lda.senate.gov/api/v1/clients/197319/","client_id":12,"name":"ABBVIE INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-02-25"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R. S.142, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 830, Help Ensure Lower Patient Copays Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}